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Abstract 12 
The permeation of ten model drugs through silicone membrane was analysed to investigate 13 
the effect of the presence of a biosurfactant obtained from corn steep liquor. The ten selected 14 
pharmaceutical compounds were chosen to include a diverse range of physicochemical 15 
properties, such as variable hydrophobicities, pKa’s, molecular masses and degrees of 16 
ionisation. When compared with compound permeation alone, the additional inclusion of 17 
biosurfactant in the donor phase altered the rate and extent of permeation. It significantly 18 
enhanced permeation for five of the compounds, whereas it decreased permeation for four of 19 
the compounds and remained approximately the same for the tenth compound. These effects 20 
were observed at both biosurfactant concentrations considered, namely 0.005 mg/mL, i.e. 21 
below the critical micellar concentration (CMC) and 0.500 mg/mL, i.e. above the CMC of the 22 
biosurfactant. Upon analysing permeation change with respect to physicochemical properties 23 
of the compounds, it was determined that compounds with a relative molecular mass below 24 
200 resulted in an increase in permeation with biosurfactant present, and those above 200 25 
resulted in a decrease in permeation with biosurfactant present. This effect was therefore 26 
attributed to the formation of a drug-biosurfactant interaction that enhanced permeation of 27 
smaller compounds, yet retarded permeation for those with a higher molecular mass. These in 28 
vitro findings can be considered an indication of potential novel formulation options that 29 
incorporate biosurfactant to create transdermal products that have bespoke permeation 30 
profiles. 31 
Keywords: PDMS; biosurfactant; permeation; membrane; polydimethylsiloxane; flow-32 
through diffusion. 33 
Statistical Summary: words = 5045, tables = 4, figures = 3 (+1 supp)  34 
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 35 
Introduction 36 
Biosurfactants are natural detergents composed of lipids, sugars and/or proteins [1]. They are 37 
known for being more biocompatible than their chemical homologues, such as sodium 38 
dodecyl sulphate (SDS), themselves used in pharmaceutical formulations to solubilise active 39 
ingredients and improve permeation through skin.  40 
Biosurfactants display similar properties to the more well-known standard surfactants. 41 
However, they are produced by microorganisms, and composed of biomolecules, being less 42 
toxic, more biocompatible, and biodegradable than chemical surfactants [2]. Many studies 43 
have demonstrated the potential uses of biosurfactants in different fields, including 44 
environmental applications [3, 4], the food industry [5, 6] and cosmetic formulations [7, 8]. 45 
However, very limited research exists regarding the application of biosurfactants in the 46 
pharmaceutical industry. Related to the applications of biosurfactants in these two last areas, 47 
some researchers have observed an antimicrobial activity of several biosurfactants against 48 
pathogenic strains [9-11]. Additionally, researchers have discovered that a biosurfactant 49 
obtained from corn steep liquor (CSL) exhibits sunscreen protective properties [12]. Corn 50 
steep liquor is a corn stream, obtained from the corn wet-milling industry, spontaneously 51 
fermented by lactic acid bacteria, which is “Generally Recognized As Safe” (GRAS) by the 52 
US Food and Drug Administration (FDA). Furthermore, the same authors have observed that 53 
it is adsorbed on hair, potentially encouraging the permeation of compounds through the skin 54 
[13, 14]. 55 
 56 
It is widely known that the permeation of a compound (both in vitro and in vivo) can be 57 
dramatically affected by the additional presence of other compounds, known as permeation 58 
enhancers [15] or retarders [16], including groups of molecules such as surfactants [17].  59 
Surfactants are compounds with surface-active properties and are known to affect the rate and 60 
extent of permeation. For this reason, surfactants are widely used in topical formulations [18]. 61 
Although they have been shown to enhance permeation under certain circumstances, many 62 
studies have demonstrated that their topical use, in cosmetic or pharmaceutical products, can 63 
be a problematic issue for the patient, sometimes causing unwanted side effects such as 64 
contact dermatitis and irritation [19]. For this reason new detergents, such as biosurfactants, 65 
that avoid these issues, are currently highly desirable as one potential solution for drug 66 
delivery [20],  although their effect on skin permeation is yet unknown. 67 
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Skin is the largest organ in the human body, generally seen as a useful barrier against the 68 
unwanted transfer of undesirable contaminants. However, dermatological pharmaceutical 69 
formulations, such as foams, creams and gels, can take advantage of the skins permeation 70 
potential for systemic delivery, often chosen because of their non-invasive nature and ease of 71 
application for the patient with anticipated growth in the market [21]. In order to study the 72 
permeation behaviour of compounds and formulations considered for transdermal delivery, 73 
human skin models are viewed as the best surrogate for clinical data [22, 23], yet present 74 
many ethical, economic and technical problems concerning availability [24]. For example, 75 
skin samples require complex storage, suffer from reproducibility as a consequence of 76 
variations in skin absorption across different body sites and can be costly studies to 77 
undertake. For this reason the majority of transdermal analysis is undertaken using animal 78 
skin, such as pig, mouse, rat, guinea pig or even snake skin [25]. However, animal tissues 79 
also have several disadvantages and challenges, with the most significant issue being the 80 
frequent lack of correlation between human and animal skin data [26]. In recent years, several 81 
in vitro techniques have been developed to determine topical permeation data, thus avoiding 82 
(incomparable) animal or (complex) human models [27]. One such group of alternatives is 83 
based on the use of polymer materials [28], including polydimethoxysiloxane (PDMS), as a 84 
barrier membrane for permeation that can be used in diffusion systems. PDMS represents a 85 
simple alternative option (in comparison with the systems previously discussed) overcoming 86 
many of their disadvantages such as cost, complexity and ethical considerations. Moreover, 87 
PDMS is particularly useful for studying basic permeation mechanisms, and ranking drugs 88 
and formulations through comparison of their permeation profiles [16, 29, 30]. For example, 89 
PDMS membrane has been reported to produce data displaying a good correlation with an in 90 
vivo system whereby the penetrant lipophilicity was the prime determinant of compound 91 
permeation [31]. 92 
Therefore, the aim of this work was to evaluate the effect of a biosurfactant extract obtained 93 
from a corn wet-milling industry stream, on the permeation of a set of model drugs, through a 94 
silicone membrane-based diffusion system. Ten compounds were selected for analysis that 95 
covered a wide range of physicochemical properties such as variations in hydrophobicity 96 
(reflected in logP values), degrees of ionisation (reflected in pKa values), molecular mass and 97 
polar surface area, along with the relative acidity/basicity of the compound. This resulted in a 98 
set of model compounds that would ultimately facilitate the analysis of a relationship 99 
between the degree of permeation and the compounds properties driving the process. The ten 100 
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compounds analysed in this work were: benzocaine, benzoic acid, benzotriazole, caffeine, 101 
ibuprofen, indomethacin, lidocaine, procaine, salicylic acid and tetracaine.  102 
Overall, in this study, the permeation of ten compounds through PDMS was measured in the 103 
presence and absence of two concentrations of an extracted biosurfactant, i.e. above and 104 
below its critical micellar concentration (CMC), in order to establish the effect of 105 
biosurfactant presence and micelle formation in permeation studies. 106 
Materials and Methods  107 
Materials 108 
Polydimethylsiloxane membrane (PDMS) was used as purchased (ATOS Medical, Sweden) 109 
with a standard thickness of 130 µm and cut to size as required. Ten pharmaceutical 110 
compounds were analysed in this study namely: benzocaine (Sigma Aldrich), benzoic acid 111 
(Sigma Aldrich), benzotriazole (Sigma Aldrich), caffeine (Sigma Aldrich), ibuprofen 112 
(BASF), indomethacin (Sigma Aldrich), lidocaine (Sigma Aldrich), procaine (Sigma 113 
Aldrich), salicylic acid (Sigma Aldrich) and tetracaine (Sigma Aldrich), all with a minimum 114 
purity of 99 %. Buffer (0.02 M, pH 7.4) consisted of dipotassium hydrogen phosphate (> 98 115 
%, Fisher Scientific) and monopotassium hydrogen phosphate (> 99 %, Fisher Scientific) 116 
with 0.1 M sodium chloride (> 99 % Sigma Aldrich).  117 
The biosurfactant extract was obtained from corn steep liquor (CSL) provided by Santa Cruz 118 
Biotechnology (Lot L1813), using chloroform stabilised with amilene (150 ppm) as organic 119 
solvent (Scharlab). 120 
Methods 121 
Biosurfactant extraction from corn steep liquor 122 
For obtaining the biosurfactant, CSL with a solid content of 50 % was subjected to an 123 
extraction process following the protocol established by Vecino et al., [32]. For that, CSL 124 
was diluted in distilled water up to 50 mg/mL. Then, 250 mL of this solution was extracted 125 
with chloroform at 56 ºC for 1 hour with a CSL:chloroform ratio 2:1 (v/v), in a KS 4000 ic 126 
control shaker (IKA, Germany). Finally, the chloroform-CSL mixture was decanted for 12 127 
hours. Once the biosurfactant was extracted, the organic solvent was eliminated by vacuum 128 
distillation obtaining an oily biosurfactant extract.  129 
Physical characterisation of biosurfactant extract  130 
The surfactant activity of extract from CSL was measured using the Wilhelmy plate method 131 
and a tensiometer K20 (Kruss). For that, the biosurfactant was dissolved in water at 132 
concentrations from 0.01 to 1 mg/mL (the concentrations prepared were 0.01; 002; 0.05; 0.1; 133 
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0.125; 0.166; 0.2; 0.25; 0.5 and 1 mg/mL), in order to obtain its critical micellar 134 
concentration (CMC), with all measurements carried out in triplicate. 135 
The pH of biosurfactant was measured using a calibrated pH meter Basic 20 (Crison) and its 136 
ionic charge was determined using ion exchange resins following the established protocol 137 
[33]. The resins used for studying the ionic charge of the bisourfactant were IR 120 (cationic 138 
exchange resin) and IRA 400 (anionic exchange resin). For these measurements 10 mL of 139 
biosurfactant was dissolved at concentrations of 1 mg/mL in distilled water and were placed 140 
in contact with 1 g of resins, observing changes in the surface tension of water after 30 min. 141 
As surface tension is directly related to the amount of biosurfactant entrapped by the resin, 142 
this parameter allowed determination of the presence (or absence) of biosurfactant in the 143 
remaining solution. 144 
Chemical characterisation of biosurfactant extract 145 
The fatty acid composition of the biosurfactant was analysed using gas chromatography 146 
coupled to a mass spectrometer (CG-MS, Bruker Scion 451-GC) and following ISO-12966-147 
3:2009. 10 mg of sample was diluted in 500 μL of tert-butyl methyl ether (TBME), and 250 148 
μL of trimethylsulfonium hydroxide (TMSH). A volume of 1 μL of the sample was injected 149 
in split less mode, and the separation of fatty acid methyl esters (FAMEs) was carried out. 150 
The column used was a DB-WAX (30 m x 0.25 mm i.d. x 0.25 μL film thickness), heated to 151 
250 ºC at a rate of 4 ºC/min. The carrier gas was helium, with a flow rate of 1 mL/min. A 152 
temperature of 250 ºC was set for the injector inlet and the transfer line of the detector.  153 
Finally, a mass selective detector was used for mass spectra acquisition, over an m/z range of 154 
50-400, and under electron impact ionisation at a voltage of 70 eV. FAMEs were identified 155 
by comparison of retention time and mass spectra of a FAME standard mix (Supelco 37 156 
Component FAME Mix: 10 mg mL of the FAME reference standard mix in methylene 157 
chloride, Sigma-Aldrich). This standard mix includes the fatty acid methyl esters reflected in 158 
Table 1. The software employed was MS Data Review (Version 8.1).  159 
 160 
Table 1: Composition of Supelco 37 FAME Standard Mix. 161 
Compound Concentration (wt %) 
cis-13,16.docosadienoic acid methyl ester 2 
cis-4,7,10,13,16,19-docosahexaenoic acid methyl ester 2 
cis-11,14-Eicosadienoic acid methyl ester 2 
cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 
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cis-8,11,14-Eicosatrienoic acid methyl ester 2 
cis-11,14,17-Eicosatrienoic acid methyl ester 2 
cis-11-Eicosenoic acid methyl ester 2 
Methyl cis-10-heptadecenoate  2 
Methyl hexanoate 4 
Methyl γ-linolenate 2 
Methyl arachidate 4 
Methyl arachidonate 2 
Methyl behenate 4 
Methyl behenate 4 
Methyl decanoate 4 
Methyl dodecanoate 4 
Methyl elaidate 2 
Methyl erucate 2 
Methyl heneicosanoate 2 
Methyl heptadecanoate 2 
Methyl linoleate 2 
Methyl linolelaidate 2 
Methyl linolenate 2 
Methyl myristate 4 
Methyl myristoleate 2 
Methyl oleate 4 
Methyl octanoate 4 
Methyl palmitate 6 
Methyl palmitoleate 2 
Methyl pentadecanoate 2 
Methyl cis-10-pentadecenoate 2 
Methyl stearate 4 
Methyl tricosanoate 2 
Methyl tetracosanoate 4 
Methyl tridecanoate 2 
Methyl undecanoate 2 
7 
 
Methyl cis-15-tetracosenoate 2 
 162 
The functional groups of the biosurfactant were analysed by Fourier-transform infrared 163 
spectroscopy (FTIR). For that, pellets containing 1 mg of biosurfactant and 10 mg of 164 
potassium bromide were prepared. Infrared absorption analysis was carried out with a 165 
Niocolet 6700 FTIR system (Thermo Scientific) from 400 to 4000 cm-1, with a spectral 166 
resolution of 4 cm-1. 167 
Permeation experiments  168 
PDMS membrane was soaked in phosphate buffer solution for 30 minutes prior to being 169 
mounted in the flow-through diffusion cells (PermeGear Inc., USA). After assembly the cells 170 
were placed on a cell warmer, maintained at 32 °C. 0.8 mL of the donor solution containing 171 
model compound and biosurfactant (except in the control, which contained only model 172 
compound) was added to the cell. In all experiments, saturated drug solutions were prepared 173 
whereby the resultant concentration of the model compounds in the donor solution was 174 
between 1.2 and 31.9 mg/mL with biosurfactant extract present at concentrations of 0.005 175 
mg/mL or 0.500 mg/mL. Phosphate buffer saline was pumped through the cells at ≤ 5.0 176 
mL/h. Samples were collected by means of a fraction collector every 45 minutes for a total of 177 
6 hours. Quantification was undertaken using UV spectroscopy (Agilent Cary 60 fitted with a 178 
Cary single cell Peltier) with the sample compartment maintained at 35 ºC at the determined 179 
λmax for each compound. All experiments were conducted in triplicate with the mean value 180 
shown and standard deviation based error limits. All flow-through cells used in this study had 181 
a diffusion area of 0.554 cm2. 182 
 183 
Results & Discussion 184 
Characterisation of biosurfactant extract  185 
The industrial applications of biosurfactants will depend on their properties, including their 186 
composition, their ionic charge, CMC, and ability to form micelles at low concentrations. For 187 
example, those biosurfactants with lower CMCs will produce micelles at a comparatively low 188 
concentration which is favourable from an industrial point of view. The biosurfactant under 189 
evaluation was found to have a CMC of 0.1198 mg/mL, which is very low in comparison 190 
with other biosurfactants reported in literature. For instance, researchers have reported that a 191 
biosurfactant produced by Lactococcus lactis exhibits a CMC of 14 mg/mL [34], whereas 192 
Madhu and Prapulla [35] reported that a biosurfactant produced by Lactobacillus plantarum 193 
8 
 
has a CMC of 6 mg/mL. Biosurfactants produced by lactic acid bacteria are of particular 194 
interest for comparative analysis with the biosurfactant under evaluation in this work because 195 
lactic acid bacteria are also known to be involved during the steeping process of corn.  196 
Another important characteristic of biosurfactants is their ionic charge. Surfactants are 197 
amphipathic molecules consisting of hydrophobic (oil soluble) and hydrophilic (water 198 
soluble) moieties in one molecule. According to their charge, surfactants can be classified as 199 
anionic, cationic, non-ionic or amphoteric [36]. The biosurfactant under evaluation in this 200 
work was found to be amphoteric as it was entrapped by anionic and cationic resins. More 201 
specifically, IRA400 was able to entrap 75 % of the biosurfactant present in the solution, 202 
whereas IR120 entrapped 62 % of biosurfactant. These results demonstrate the amphoteric 203 
nature of this biosurfactant, which is in concordance with data previously reported [33]. 204 
Amphoteric surfactants are ideal excipients, widely used in personal care products, as they 205 
tend to be less irritating to skin and eyes, have high biological compatibility and low toxicity 206 
in comparison with other types of surfactants [37]. A summary of the properties of the 207 
biosurfactant extracted for this study is shown in Table 2. 208 
Table 2: Physical properties of the biosurfactant extract used in this work. 209 
Critical Micellar Concentration (mg/mL) 0.1198 (± 0.026) 
Minimum Surface Tension (mN/m) 41.8 (± 0.4) 
pH 4.5 
Adsorption on IRA (400) positive 
Adsorption on IR 120  positive 
Related to the fatty acid composition, FAME analysis confirmed that fatty acids represented 210 
almost 43 % of the biosurfactant extract. These fatty acids contained 16 and 18 C units, such 211 
as palmitic, stearic, oleic, and linolelaidic acids, which represented 2 %, 7 %, 12 % and 22 % 212 
of the biosurfactant extract, respectively. These results confirm that this extract has a 213 
significant lipophilic character, as seen previously [33, 38]. As a result of the lipidic nature of 214 
this biosurfactant, it is proposed that it could improve the permeation of drugs through the 215 
skin. This theory is based upon the knowledge that the stratum corneum of skin is composed 216 
of lipidic compounds such as cholesterol and similar fatty acids to those found in this 217 
biosurfactant extract [39].  218 
FTIR analysis of the biosurfactant extract (Supplementary Figure S1) displayed similar 219 
absorption bands to those obtained in previous work, demonstrating that the production of 220 
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this bisourfactant extract in corn steep liquor is regular and homogeneous [40]. The FTIR 221 
spectrum presented strong absorption bands between 3000 cm-1 and 2700 cm-1, indicating the 222 
presence of carboxylic acids present in fatty acid esters and proteins, along with an 223 
absorption band at ~1700 cm-1 indicative of C=O stretch. Absorption bands between 1500 224 
cm-1 and 1300 cm-1 are indicative of symmetric and asymmetric N-O stretch, present in 225 
amino acids.  226 
Permeation properties 227 
It should firstly be noted that as the amount permeated varied (depending upon solubility in 228 
the modified buffer solution), all comparative analysis was undertaken by comparing the 229 
percentage change in amount rather than the mass permeated per cm2. For five of the ten 230 
compounds analysed, the presence of the biosurfactant significantly increased the cumulative 231 
amount of compound permeated after six hours, compared with drug alone. The increase in 232 
cumulative permeation did appear to vary depending upon the compound under investigation, 233 
ranging from a maximum increase for benzoic acid of 47 % (Figure 1) through to only a 15 % 234 
maximum increase for salicylic acid. The increase in amount permeated also appeared to be 235 
dependent upon the amount of biosurfactant present, as the addition of 0.500 mg/mL had a 236 
more profound effect on permeation compared with the addition of 0.005 mg/mL 237 
biosurfactant. For lidocaine, the presence of 0.005 mg/mL biosurfactant had no effect on 238 
permeation, and interestingly, for salicylic acid the lower biosurfactant concentration 239 
increased permeation to a greater extent than that for the higher concentration solution. This 240 
could be explained by changes produced in the micelle size, due to an increase in the number 241 
of aggregated biosurfactant molecules. For example, Sanchez et al., [41] have reported the 242 
formation of larger aggregates at concentrations above the CMC for dirhamnolipid produced 243 
by Peudomonas aeruginosa. Despite the fact that the maximum concentration of 244 
biosurfactant employed was more than 5 times lower than the CMC, Malcher and  Gzyl-245 
Malcher [42] have also observed that salicylate ions facilitate the formation of polymer-246 
micelle aggregates by screening the electrostatic repulsions between the charge surfactant 247 
head groups. Thus, in this case, salicylic acid contributed to the formation of aggregates 248 
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through a synergistic effect to a much greater extent than other compounds. 249 
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Figure 1: Cumulative amount permeated over six hours for benzoic acid in buffer (■), in the 251 
presence of 0.005 mg/mL surfactant (●) and 0.500 mg/mL surfactant (▲), n = 3 and ± = SD.  252 
The cumulative amount percentage increases in permeation for the five compounds (where an 253 
increase was observed) are summarised in Table 3. 254 
Table 3: Cumulative amount percentage increase after six hours for the five compounds that 255 
displayed an increase in permeation in the presence of biosurfactant. 256 
Compound % increase in cumulative permeation 
after six hours in the presence of 
0.005 mg/mL biosurfactant 
% increase in cumulative permeation 
after six hours in the presence of 
0.500 mg/mL biosurfactant 
Benzocaine 23 (± 1 %) 37 (± 2 %) 
Benzoic Acid 31 (± 5 %) 47 (± 1 %) 
Caffeine 17 (± 6 %) 25 (± 7 %) 
Lidocaine -6 (± 1 %) 24 (± 7 %) 
Salicylic Acid 43 (± 6 %) 15 (± 4 %) 
For one of the ten compounds analysed, namely benzotriazole, the presence of the 257 
biosurfactant had no significant effect on the cumulative amount of compound permeated 258 
after six hours compared with compound alone (Figure 2). This compound is known to self-259 
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assemble in aqueous solution to form aggregated structures [43] which may have affected the 260 
permeation process. 261 
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Figure 2: Cumulative amount permeated over six hours for benzotriazole in buffer (■), in the 263 
presence of 0.005 mg/mL surfactant (●) and 0.500 mg/mL surfactant (▲), n = 3 and ± = SD. 264 
For the remaining four of the ten compounds analysed the presence of the biosurfactant 265 
significantly decreased the cumulative amount of compound permeated after six hours 266 
compared with compound alone. The decrease in cumulative permeation once again, did 267 
appear to vary depending upon the compound under investigation ranging from a maximum 268 
decrease for procaine of 36 % (Figure 3), through to only a 13 % maximum decrease for 269 
ibuprofen. Furthermore, the decrease in amount permeated appeared to be less dependent 270 
upon the amount of surfactant present (compared with the compounds where an increase in 271 
permeation was observed), whereby the addition of 0.500 mg/mL only decreased permeation 272 
for one of the compounds (indomethacin) compared with the addition of 0.005 mg/mL 273 
biosurfactant. 274 
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Figure 3: Cumulative amount permeated over six hours for procaine in buffer (■), in the 276 
presence of 0.005 mg/mL surfactant (●) and 0.500 mg/mL surfactant (▲), n = 3 and ± = SD.   277 
 278 
The cumulative amount percentage decreases in permeation for the four compounds (where a 279 
decrease was observed) are summarised in Table 4. 280 
 281 
Table 4: Cumulative amount percentage decrease after six hours for the four compounds that 282 
displayed a decrease in permeation in the presence of biosurfactant. 283 
Compound % decrease in cumulative permeation 
after six hours in the presence of 
0.005 mg/mL biosurfactant 
% decrease in cumulative permeation 
after six hours in the presence of 
0.500 mg/mL biosurfactant 
Ibuprofen 23 (± 2 %) 13 (± 1%) 
Indomethacin  21 (± 6 %) 28 (± 3 %) 
Procaine 42 (± 1 %) 36 (± 3 %) 
Tetracaine 17 (± 5 %) 16 (± 4 %) 
 284 
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To explain why the ten compounds exhibited such variable effects in the presence of 285 
biosurfactant several physicochemical properties relating to the compounds were considered, 286 
including lipophilicity, degree of ionisation at the experimental pH, pKa, solubility, polar 287 
surface area and molecular mass. For example, it is interesting to note that procaine has a 288 
similar chemical structure to lidocaine with the minor difference being an amine and ester 289 
group on the former and an amide on the latter. This does result in procaine being less 290 
lipophilic than lidocaine and assuming the two drugs each bind to the micelle through 291 
electrostatic attractions, it may be that procaine has a greater preference to remain in the 292 
aqueous phase, rather than being incorporated within micelles and is therefore not 293 
encouraged to permeate. However, lipophilicity was deemed not to be a determining factor as 294 
to whether a compound experienced an increase or decrease in permeation. For example, a 295 
similar decrease in permeation was observed for indomethacin and procaine at the higher 296 
biosurfactant concentration, yet the two compounds have significantly different lipophilicities 297 
(calculated using Advanced Chemistry Development, Inc. (ACD/Labs) to be 4.3 and 3.1 298 
respectively). 299 
After analysing all of these factors it was found that the primary factor dictating permeation 300 
was the relative molecular mass of the compound. For the five compounds that experienced 301 
an increase in permeation in the presence of surfactant, the relative molecular mass was 302 
below 200 whereas for the four that experienced a decrease in permeation the relative 303 
molecular mass was above 200. However, there was one exception to this correlation, namely 304 
lidocaine, with a relative molecular mass of 234 and a maximum increase in permeation of 24 305 
%. This anomaly may be a consequence of the amphiphilic nature of the drug allowing it to 306 
interact to a greater extent than anticipated with the biosurfactant. It is theorised that in 307 
general, a strong interaction was possible between a compound and the biosurfactant if the 308 
compound was relatively small (as indicated by a comparatively small relative molecular 309 
mass) and it is this interaction that helps encourage permeation to occur. In contrast, for the 310 
four compounds with comparatively high molecular masses, i.e. > 200, the compound-311 
biosurfactant interaction either did not occur or resulted in a large, complex structure that 312 
struggled to permeate the silicone membrane. This theory fits well with that previously 313 
published in literature where the correlation between reduced diffusion with increasing 314 
penetrant size is well documented [44]. Overall, the findings presented in this work indicate 315 
that there is potential for the application of biosurfactants within formulations as an aid to 316 
modify transdermal permeation and that this effect can be controlled by the choice of 317 
compound selected. 318 
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 319 
Conclusion 320 
 In summary, the cumulative amount of permeation for ten compounds through silicone 321 
membrane in the absence and presence of a naturally occurring biosurfactant was analysed. 322 
Overall, the effect on permeation appeared to vary between the compounds, increasing 323 
permeation in some cases yet decreasing permeation in others, possibly linked to the 324 
compounds relative molecular mass as a reflection of molecular size. It would appear that 325 
those with a comparatively small mass are able to permeate more easily and to a greater 326 
extent, possibly through favourable compound-biosurfactant interactions, whereas the reverse 327 
scenario is true for compounds of a high molecular mass in that permeation is retarded.  328 
These findings are of interest for those considering the incorporation of biosurfactants in 329 
pharmaceutical, cosmetic or household products. There are many reasons why biosurfactants 330 
could be used within formulations, for example their low toxicity, ability to biodegrade and 331 
biocompatibility. However, it should also be considered that they can be more complex to 332 
obtain in a pure form, with variable composition and expensive to extract on a large scale. 333 
Overall though, the advantages offered by the inclusion of biosurfactants are significant and it 334 
is anticipated that more and more biosurfactant-based products will appear in future years. 335 
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